Dr. Ch. Efthimiadhis na paraqet historine disa vjecare te trajtimit me Vidatox te motres se tij, paciente ne kliniken tone, e diagnostikuar me Glioblastoma multiforme (tumor malinj i trurit) 10 vjet me pare. 3 vitet e fundit ajo eshte nen trajtimin me Vidatox. Ai shprehet: “…Nuk e di nese eshte pergjegjes Vidatox apo ne jetuam nje mrekulli,...

Dr. Ch. Efthimiadhis
Sep 12, 2015


Heberprot-P is a patended pharmaceutical composition whose parenteral formulation is based on rhEGF. The product is administered in diabetic foot ulcer patients by intralesional infiltration to accelerate healing of deep and complex ulcers, either neuropathic or ischemic.

What is the diabetic foot ulcer? 

If you have diabetes, your blood glucose, or blood sugar, levels are too high. Over time, this can damage your nerves or blood vessels. Nerve damage from diabetes can cause you to lose feeling in your feet. You may not feel a cut, a blister or a sore. Foot injuries such as these can cause ulcers and infections. Serious cases may even lead to ampilation. Ischemic diabetic foot ulcer is the most difficult to treat and confers the highest ampulation risk.

Antimicrobial agents, surgical techniques and broad variety of therapeutic approaches based on drugs and devices have been applied to diabetc foot ulcers. These intervations have shown limited clinical success.

Evidence shows that diabetic paients have decreased concentrations of growth factors in their tissues, notably epidermal growth factor. This shortage impairs natural wound healing and leads to chronic nonhealing wounds, diabetic foot ulcers, which in later stages can require limb ampulation. Injecting epidermal growth factor deep into the would bottom and contours encourages a more effective pharmacodynamic response in terms of granulation tissue growth and would closure.

Heberprot-P is an innovative, safety and efficasiously  Cuban product containg recombinant human epidermal growth factor for peri- and intra-lesional infiltration.

Why Heberprot –P ?

Local infiltrations of hrEGF have shown to be effective to reduce the consequences of neurogenic ischemia, and to protect peripheral soft tissue. Pre-clinical evidences allowed developing the product Heberprot-P, a pharmaceutical  formulation containing hrEGF to be applied through peri and intralesional infiltration, which consitutes a treatment to accelerate the healing deep and complex ulcers, including ischemic and neuropathic ulcers, derived from this metabolic disorder. After proof of concept demostrated that Heberprot-P contributed to the restoration of the granulation tissue, which is the joining material of tissues after open traumas.



How much time takes the Heberprot-P’ s action?

Every action performed by EGF depends on the phosphorylation of the TYROSINE KINASE domain of the receptor stationarily exposed. The reaction time of the Tyrosine phosphorylation process is lower than 1 minute in vitro. In most studied cell lines, the process starts to turn off after 30 minutes. However, while this takes place, there is a wide range of transduction and accessory proteins in the cytoplasm that have just been phosphorylated, and activated, which equally takes place in Transcription Factors. It is not easy to establish a time frame for these actions, because they depend on many biological phenomena. However, investigations using pharmacokitenic and pharmacodinamics modelling in murine models with acute and controlled wounds have shown, since 1985, that fibroblast proliferation demands receptor activation during hours.


Heberprot-P is a unique and first-in-class therapy to treat the most compilated and recalcitrant chronic wounds with a high risk of ampulation.


Copyright © 2018 Klinika Kubane San Marco 2015. All Right Reserved.